Electromed (Electromed) ROCE %

: 23.01% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Electromed's annualized ROCE % for the quarter that ended in Dec. 2023 was 23.01%.

Electromed ROCE % Historical Data

The historical data trend for Electromed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Electromed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

11.71

18.28

10.01

8.91

11.14

Electromed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															14.65	13.32	16.11	1.49	23.01

Electromed ROCE % Calculation

Electromed's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	4.008	/	( ( (41.364 - 7.15)	+	(45.806 - 8.053) )	/ 2 )
	=	4.008	/	( (34.214	+	37.753)	/ 2 )
	=	4.008	/	35.9835
	=	11.14 %

Electromed's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	9.052	/	( ( (44.066 - 5.776)	+	(46.964 - 6.573) )	/ 2 )
	=	9.052	/	( ( 38.29	+	40.391 )	/ 2 )
	=	9.052	/	39.3405
	=	23.01 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Electromed (AMEX:ELMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Electromed ROCE % Related Terms

Thank you for viewing the detailed overview of Electromed's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Electromed (Electromed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Electromed Inc (AMEX:ELMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Sixth Avenue NW, New Prague, MN, USA, 56071

Website

https://www.smartvest.com

Electromed Inc is a United States-based company that develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.

Executives

Andrew Summers	director	601 JEFFERSON STREET, HOUSTON TX 77002
James L. Cunniff	director, officer: CEO and President	500 SIXTH AVE NW, NEW PRAGUE MN 56071
Kathleen Skarvan	officer: Chief Executive Officer	40 WEST HIGHLAND PARK DR NE, HUTCHINSON MN 55350
Bradley M. Nagel	officer: Chief Financial Officer	500 SIXTH AVE NW, NEW PRAGUE MN 56071
Michelle C. Wirtz	officer: Chief Financial Officer	500 SIXTH AVENUE NW,, NEW PRAGUE MN 56071
Christopher G. Holland	officer: Chief Commercial Officer	500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Joseph L. Galatowitsch	director	500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Kathleen A Tune	director	60 SOUTH SIXTH STREET, SUITE 3620, MINNEAPOLIS MN 55402
A Jones Lee	director	54 LOCKE LAKE RD, FRIDLEY MN 55432
Stephen H. Craney	director	25340 SANDPIPER LANE, WINONA MN 55987
Andrea M. Walsh	director	500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
George H. Winn	director	27451 COUNTRY HOLLOWS LANE, NEW PRAGUE MN 56701
Michael Joseph Maccourt	officer: Chief Financial Officer	500 SIXTH AVENUE NW, NEW PRAGUE MN 56071
Gregory Fluet	director	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
John L Erb	director	C/O VASCULAR SOLUTIONS, INC., 6464 SYCAMORE COURT N., MINNEAPOLIS, MN 55369

Electromed (Electromed) Headlines

From GuruFocus

Electromed Stock Gives Every Indication Of Being Significantly Overvalued

By GF Value GF Value • 04-06-2021

Electromed Stock Appears To Be Significantly Overvalued

By GF Value GF Value • 06-06-2021

Electromed Inc (ELMD) Reports 16% Revenue Growth in Q1 FY 2024

By GuruFocus Research • 11-07-2023

Sidoti Virtual Microcap Investor Conference

By ACCESSWIRE ACCESSWIRE • 11-19-2020